Literature DB >> 7966591

The p2 domain of human immunodeficiency virus type 1 Gag regulates sequential proteolytic processing and is required to produce fully infectious virions.

S C Pettit1, M D Moody, R S Wehbie, A H Kaplan, P V Nantermet, C A Klein, R Swanstrom.   

Abstract

The proteolytic processing sites of the human immunodeficiency virus type 1 (HIV-1) Gag precursor are cleaved in a sequential manner by the viral protease. We investigated the factors that regulate sequential processing. When full-length Gag protein was digested with recombinant HIV-1 protease in vitro, four of the five major processing sites in Gag were cleaved at rates that differ by as much as 400-fold. Three of these four processing sites were cleaved independently of the others. The CA/p2 site, however, was cleaved approximately 20-fold faster when the adjacent downstream p2/NC site was blocked from cleavage or when the p2 domain of Gag was deleted. These results suggest that the presence of a C-terminal p2 tail on processing intermediates slows cleavage at the upstream CA/p2 site. We also found that lower pH selectively accelerated cleavage of the CA/p2 processing site in the full-length precursor and as a peptide primarily by a sequence-based mechanism rather than by a change in protein conformation. Deletion of the p2 domain of Gag results in released virions that are less infectious despite the presence of the processed final products of Gag. These findings suggest that the p2 domain of HIV-1 Gag regulates the rate of cleavage at the CA/p2 processing site during sequential processing in vitro and in infected cells and that p2 may function in the proper assembly of virions.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7966591      PMCID: PMC237265          DOI: 10.1128/JVI.68.12.8017-8027.1994

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

Review 1.  Efficient site-directed mutagenesis using uracil-containing DNA.

Authors:  T A Kunkel; K Bebenek; J McClary
Journal:  Methods Enzymol       Date:  1991       Impact factor: 1.600

2.  A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base.

Authors:  R A Poorman; A G Tomasselli; R L Heinrikson; F J Kézdy
Journal:  J Biol Chem       Date:  1991-08-05       Impact factor: 5.157

3.  Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid.

Authors:  S C Pettit; J Simsic; D D Loeb; L Everitt; C A Hutchison; R Swanstrom
Journal:  J Biol Chem       Date:  1991-08-05       Impact factor: 5.157

4.  Analysis of subsite preferences of HIV-1 proteinase using MA/CA junction peptides substituted at the P3-P1' positions.

Authors:  A Billich; G Winkler
Journal:  Arch Biochem Biophys       Date:  1991-10       Impact factor: 4.013

5.  Mutagenesis of protease cleavage sites in the human immunodeficiency virus type 1 gag polyprotein.

Authors:  R J Tritch; Y E Cheng; F H Yin; S Erickson-Viitanen
Journal:  J Virol       Date:  1991-02       Impact factor: 5.103

6.  Comparison of the HIV-1 and HIV-2 proteinases using oligopeptide substrates representing cleavage sites in Gag and Gag-Pol polyproteins.

Authors:  J Tözsér; I Bláha; T D Copeland; E M Wondrak; S Oroszlan
Journal:  FEBS Lett       Date:  1991-04-09       Impact factor: 4.124

7.  Human immunodeficiency virus-1 protease. 2. Use of pH rate studies and solvent kinetic isotope effects to elucidate details of chemical mechanism.

Authors:  L J Hyland; T A Tomaszek; T D Meek
Journal:  Biochemistry       Date:  1991-08-27       Impact factor: 3.162

8.  Purification and biochemical characterization of recombinant simian immunodeficiency virus protease and comparison to human immunodeficiency virus type 1 protease.

Authors:  S K Grant; I C Deckman; M D Minnich; J Culp; S Franklin; G B Dreyer; T A Tomaszek; C Debouck; T D Meek
Journal:  Biochemistry       Date:  1991-08-27       Impact factor: 3.162

9.  Bovine leukemia virus matrix-associated protein MA(p15): further processing and formation of a specific complex with the dimer of the 5'-terminal genomic RNA fragment.

Authors:  I Katoh; H Kyushiki; Y Sakamoto; Y Ikawa; Y Yoshinaka
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

10.  Dynamic properties of membrane proteins: reversible insertion into membrane vesicles of a colicin E1 channel-forming peptide.

Authors:  S Xu; W A Cramer; A A Peterson; M Hermodson; C Montecucco
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

View more
  188 in total

1.  Mutations within four distinct gag proteins are required to restore replication of human immunodeficiency virus type 1 after deletion mutagenesis within the dimerization initiation site.

Authors:  C Liang; L Rong; Y Quan; M Laughrea; L Kleiman; M A Wainberg
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

2.  Altered substrate specificity of drug-resistant human immunodeficiency virus type 1 protease.

Authors:  Deborah S Dauber; Rainer Ziermann; Neil Parkin; Dustin J Maly; Sami Mahrus; Jennifer L Harris; Jon A Ellman; Christos Petropoulos; Charles S Craik
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

3.  Second-site suppressors of Rous sarcoma virus Ca mutations: evidence for interdomain interactions.

Authors:  J B Bowzard; J W Wills; R C Craven
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

4.  The dimer interfaces of protease and extra-protease domains influence the activation of protease and the specificity of GagPol cleavage.

Authors:  Steven C Pettit; Sergei Gulnik; Lori Everitt; Andrew H Kaplan
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

5.  Determinants of the human immunodeficiency virus type 1 p15NC-RNA interaction that affect enhanced cleavage by the viral protease.

Authors:  N Sheng; S C Pettit; R J Tritch; D H Ozturk; M M Rayner; R Swanstrom; S Erickson-Viitanen
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

6.  Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro.

Authors:  M Kotler; M Simm; Y S Zhao; P Sova; W Chao; S F Ohnona; R Roller; C Krachmarov; M J Potash; D J Volsky
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

7.  Cofactors for human immunodeficiency virus type 1 cDNA integration in vitro.

Authors:  Kui Gao; Robert J Gorelick; Donald G Johnson; Frederic Bushman
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

8.  Replacement of the P1 amino acid of human immunodeficiency virus type 1 Gag processing sites can inhibit or enhance the rate of cleavage by the viral protease.

Authors:  Steve C Pettit; Gavin J Henderson; Celia A Schiffer; Ronald Swanstrom
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

9.  Characterization of RNA elements that regulate gag-pol ribosomal frameshifting in equine infectious anemia virus.

Authors:  Chaoping Chen; Ronald C Montelaro
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

10.  p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease.

Authors:  M Huang; J M Orenstein; M A Martin; E O Freed
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.